Found: 5
Select item for more details and to access through your institution.
Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy.
- Published in:
- Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1261070
- By:
- Publication type:
- Article
Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy.
- Published in:
- Frontiers in Immunology, 2023, p. 01, doi. 10.3389/fimmu.2023.1261070
- By:
- Publication type:
- Article
Quantitative Systems Pharmacology Approaches for Immuno‐Oncology: Adding Virtual Patients to the Development Paradigm.
- Published in:
- Clinical Pharmacology & Therapeutics, 2021, v. 109, n. 3, p. 605, doi. 10.1002/cpt.1987
- By:
- Publication type:
- Article
First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
In situ analysis of FGFR2 mRNA and comparison with <italic>FGFR2</italic> gene copy number by dual-color in situ hybridization in a large cohort of gastric cancer patients.
- Published in:
- Gastric Cancer, 2018, v. 21, n. 3, p. 401, doi. 10.1007/s10120-017-0758-x
- By:
- Publication type:
- Article